ストックスクリーナーアプリを入手
2.30
6.48%
0.14
アフターアワーズ：
2.32
0.02
+0.87%
C 4 Therapeutics Inc (CCCC) 最新ニュース
Brookline Capital Raises Price Target for C4 Therapeutics (CCCC) to $30 | CCCC Stock News - GuruFocus
CCCC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma - Investing News Network
C4 Therapeutics doses first patient in phase 2 myeloma trial - Investing.com
C4 Therapeutics Doses First Patient in Phase 2 Trial of Cemsidomide Combination Therapy in Multiple Myeloma - marketscreener.com
Investor watch: C4 Therapeutics fireside chats in Boston and Miami - Stock Titan
New oral myeloma drug from C4 Therapeutics enters Phase 2 test - Stock Titan
What valuation multiples suggest for C4 Therapeutics Inc. stock2025 Price Action Summary & Short-Term High Return Strategies - mfd.ru
Strong Analyst Confidence in C4 Therapeutics (CCCC)’s Cemsidomide Drives 270% Upside Potential - Yahoo Finance
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Bitget
C4 Therapeutics (CCCC) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Will C4 Therapeutics Inc. stock outperform tech sector in 2025Weekly Trend Recap & High Accuracy Investment Entry Signals - mfd.ru
Retail Trends: Is C4 Therapeutics Inc. stock a buy for dividend growth2025 Biggest Moves & Verified Technical Trade Signals - mfd.ru
Is C4 Therapeutics Inc. stock dividend yield sustainable2025 Retail Activity & Smart Allocation Stock Tips - mfd.ru
What is C4 Therapeutics Inc.’s valuation compared to sectorEarnings Risk Summary & Accurate Entry/Exit Alerts - mfd.ru
Can C4 Therapeutics Inc. reach all time highs this yearWeekly Gains Summary & Weekly Top Performers Watchlists - mfd.ru
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
C4 Therapeutics Maps Cemsidomide Phase II Launch, BCMA Combo Plans at Guggenheim Conference - MarketBeat
Biotech Mineralys offers 4-year stock awards to new hires - Stock Titan
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Globe and Mail
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Institutional investors may adopt severe steps after C4 Therapeutics, Inc.'s (NASDAQ:CCCC) latest 11% drop adds to a year losses - simplywall.st
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New C4 Therapeutics hire receives options on 162,880 shares - Stock Titan
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Intellia Therapeutics
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - Investing News Network
C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewswire Inc.
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics, Inc. (CCCC): A Bull Case Theory - Finviz
2.25%
0.47%
大文字化:
|
ボリューム (24 時間):